Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -579.53% | -55.90% | 27.68% | 21.55% | 115.93% |
| Total Depreciation and Amortization | -19.14% | -5.93% | -7.76% | -4.94% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 129.10% | 199.45% | -74.01% | 1.68% | -366.17% |
| Change in Net Operating Assets | 111.29% | -168.91% | -251.87% | 373.02% | -286.49% |
| Cash from Operations | 37.21% | 2.21% | -13.91% | 55.67% | -5.46% |
| Capital Expenditure | -- | 100.00% | 100.00% | 43.26% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.29% | 177.07% | 141.11% | -52.76% | 46.21% |
| Cash from Investing | -34.24% | 176.75% | 141.08% | -52.71% | 46.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -23.79% | -- | -70.23% | -100.00% | -33.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,600.00% | -- | -70.23% | -100.00% | -98.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.18% | 91.02% | 102.75% | -100.28% | 241.08% |